Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A Disintegrin And Metalloprotease 17 (ADAM17)
- Target
- ADAM17
- Molecular classification
- Metalloprotease, Sheddase, Type I transmembrane protein
01
Overview
ADAM17, also known as TACE, is a transmembrane metalloprotease responsible for cleaving the extracellular domains of various membrane proteins, including TNF-alpha and IL-6R. This proteolytic activity regulates diverse biological processes such as inflammation, immune response, cell proliferation, and vascular biology. Dysregulation of ADAM17 is implicated in several diseases, including chronic inflammatory conditions, cancer, and metabolic disorders.
- Other names
- TACETumor Necrosis Factor-α Converting Enzyme
02
Mechanism of action
ADAM17 inhibitors block the shedding of various substrates, preventing their activation or release.
03
Biological functions
Shedding of cytokinesProteolytic processingInflammationImmune response modulationCell proliferationCell differentiationVascular remodelingMetabolic regulationEmbryonic development
04
Disease associations
Chronic inflammatory diseasesCancer progressionVascular disordersHypertensionAneurysm formationMetabolic syndromesInsulin resistancePsoriasis
05
Safety considerations
Loss-of-function mutations are lethal during embryogenesisOveractivity contributes to disease states
Beyond the preview
Go deeper on A Disintegrin And Metalloprotease 17 (ADAM17).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A Disintegrin And Metalloprotease 17 (ADAM17).